GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Apogee Therapeutics Inc (NAS:APGE) » Definitions » Shares Outstanding (EOP)

Apogee Therapeutics (Apogee Therapeutics) Shares Outstanding (EOP) : 56.37 Mil (As of Mar. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Apogee Therapeutics Shares Outstanding (EOP)?

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. Apogee Therapeutics's shares outstanding for the quarter that ended in Mar. 2024 was 56.37 Mil.

Apogee Therapeutics's quarterly shares outstanding increased from Dec. 2023 (48.52 Mil) to Mar. 2024 (56.37 Mil). It means Apogee Therapeutics issued new shares from Dec. 2023 to Mar. 2024 .

Apogee Therapeutics's annual shares outstanding increased from Dec. 2022 (27.25 Mil) to Dec. 2023 (48.52 Mil). It means Apogee Therapeutics issued new shares from Dec. 2022 to Dec. 2023 .


Apogee Therapeutics Shares Outstanding (EOP) Historical Data

The historical data trend for Apogee Therapeutics's Shares Outstanding (EOP) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Apogee Therapeutics Shares Outstanding (EOP) Chart

Apogee Therapeutics Annual Data
Trend Dec22 Dec23
Shares Outstanding (EOP)
27.25 48.52

Apogee Therapeutics Quarterly Data
Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Shares Outstanding (EOP) Get a 7-Day Free Trial 47.62 47.62 48.02 48.52 56.37

Competitive Comparison of Apogee Therapeutics's Shares Outstanding (EOP)

For the Biotechnology subindustry, Apogee Therapeutics's Shares Outstanding (EOP), along with its competitors' market caps and Shares Outstanding (EOP) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Apogee Therapeutics's Shares Outstanding (EOP) Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Apogee Therapeutics's Shares Outstanding (EOP) distribution charts can be found below:

* The bar in red indicates where Apogee Therapeutics's Shares Outstanding (EOP) falls into.



Apogee Therapeutics Shares Outstanding (EOP) Calculation

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. They have voting rights and represent ownership in the corporation by the person that holds the shares. They should be distinguished from treasury shares, which are shares held by the corporation itself, having no exercisable rights.

Shares outstanding can be calculated as either basic or fully diluted. The fully diluted shares outstanding count includes diluting securities, such as options, warrants or convertibles.

Please note: GuruFocus named Shares Outstanding (EOP) is the shares for that end of period. It is usually used to calculate balance sheet related items, such as Book Value per Share, etc. While Shares Outstanding (Diluted Average) and Shares Outstanding (Basic Average) are the weighted average shares over a period of time (a year, a quarter, or so). They are usually used to calculate income statement or cashflow statement related items, such as Earnings per Share (Diluted), etc.


Apogee Therapeutics  (NAS:APGE) Shares Outstanding (EOP) Explanation

A company may buy back shares or issue shares in any fiscal period. If a company buys back shares, we should observe that the total number of shares decline. If the company issues new shares, the number of shares outstanding increases.

Usually the presence of treasury shares and a history of buyback are good indicators that company has competitive advantage. But studies have shown that companies usually buy back at wrong time. Buying back shares below its intrinsic value increases value for remaining shareholders. Buying back overvalued shares destroys value for existing shareholders.


Be Aware

Warren Buffett looks for consistency and upward long term trend. Because of share repurchase it is possible for net earnings trend to differ from EPS trend. He preferred net income over EPS. The companies with durable competitive advantage companies report higher % net earnings to total revenues.

Important: If a company is showing net earnings history greater than 20% on total revenues, it is probably benefiting from a long term competitive advantage.

If net earnings is less than 10%, likely to be in a highly competitive business.


Apogee Therapeutics Shares Outstanding (EOP) Related Terms

Thank you for viewing the detailed overview of Apogee Therapeutics's Shares Outstanding (EOP) provided by GuruFocus.com. Please click on the following links to see related term pages.


Apogee Therapeutics (Apogee Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
221 Crescent Street, Building 17, Suite 102b, Waltham, MA, USA, 02453
Apogee Therapeutics Inc is a biotechnology company seeking to develop differentiated biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD) and related inflammatory and immunology (I&I) indications with high unmet need. Its antibody programs are designed to overcome the limitations of existing therapies by targeting well-established mechanisms of action and incorporating advanced antibody engineering to optimize half-life and other properties. Its two most advanced programs are APG777 and APG808, which they initially develop for treating AD and COPD, respectively. With its broad pipeline and depth of expertise, the company believes it can deliver value and meaningful benefits to patients underserved by today's standard of care.
Executives
Mark C. Mckenna director 400 SOMERSET CORPORATE BOULEVARD, BRIDGEWATER NJ 08807
Nimish P Shah director 7 BRYANT PARK, 23RD FLOOR, NEW YORK CITY NY 10018
Jane Henderson officer: Chief Financial Officer C/O ELEVEN BIOTHERAPEUTICS, INC., 215 FIRST STREET, CAMBRIDGE MA 02142
Peter Evan Harwin director 2001 MARKET STREET, SUITE 2500, PHILADELPHIA PA 19103
Jones William A Jr director NITROMED, INC., 125 SPRING STREET, LEXINGTON MA 02421
Fairmount Funds Management Llc director 200 BARR HARBOR DRIVE, SUITE 400, WEST CONSHOHOCKEN PA 19428
Michael Thomas Henderson director, officer: Chief Executive Officer 421 KIPLING STREET, PALO ALTO CA 94301
Fairmount Healthcare Fund L.p. director 2001 MARKET STREET, SUITE 2500, PHILADELPHIA PA 19103
Fairmount Healthcare Fund Ii L.p. director 200 BARR HARBOR DRIVE, SUITE 400, WEST CONSHOHOCKEN PA 19428
Tomas Kiselak director 2001 MARKET STREET, SUITE 2500, PHILADELPHIA PA 19103
Jennifer A. Fox director C/O NUVATION BIO INC., 1500 BROADWAY, SUITE 1401, NEW YORK NY 10036
Andrew Gottesdiener director 3340 HILLVIEW AVE, PALO ALTO CA 94304
Fairmount Healthcare Co-invest Ii L.p. director 200 BARR HARBOR DRIVE, SUITE 400, WEST CONSHOHOCKEN PA 19428
Carl Dambkowski officer: Chief Medical Officer 221 CRESCENT ST., BUILDING 17, SUITE 102B, WALTHAM MA 02453

Apogee Therapeutics (Apogee Therapeutics) Headlines